Paul G. Richardson, MD:In the context of molecular characterization of relapse, I think this is an incredibly important area. We assess bone marrow aspiration and biopsy for cytogenetics, which should include FISH [fluorescence in situ hybridization], recognizing that the more sophisticated tools that we have are not necessarily available in community practice; but certainly, FISH is. Why that’s so important is because obviously if a patient has acquired a translocation of 11;14, that’s very helpful to us. It allows us to deploy a targeted therapyspecifically, venetoclax. We know that in combination with proteasome inhibitors for patients who are t(11;14)-positive, it confers remarkable clinical benefit. The important thing to note though is in those who are not t(11;14)-positive, this has to obviously be approached with much more caution. In those patients, as best as we can tell, the impact of the drug, unfortunately, is adverse. And so, those patients should obviously not be exposed to venetoclax at this point.
Also, from the molecular characterization of disease, we learn a lot more. For example, has the patient acquired a 17p deletion? I think as most of the audience appreciates, genetics in myeloma change over time. So what your genetic characterization of the patient was at diagnosis can be fundamentally different at relapse. And so, noticing if there’s acquired 17p becomes very important. Then we know we have a high-risk situation and can adapt accordingly.
In that same spirit, if there’s t(4;14), t(14;16), these are markers of poor risk. We’re now recognizing that 1q amplification is also associated with poor risk. Conversely, obviously standard risk is none of the above, and that obviously can be helpful as well in assessing the intensity of treatment that may be required. In terms of therapeutic options, as we think about 1q amplification or 17p deletion, integrating proteasome inhibition into the algorithm really does make sense. Integrating antibodies makes great sense. Optimizing the immunomodulatory-based platform also makes sense.
Transcript edited for clarity.
Connecting Heart Disease and Hematologic Malignancies
November 28th 2023A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Read More
Selinexor-Based Triplet Therapy Improves Outcomes in Certain Patients with RRMM
November 24th 2023In the first article of a 2-part series, Sumit Madan, MD, discusses how the combination of selinexor, bortezomib, and dexamethasone shows superior survival outcomes for patients with relapsed/refractory multiple myeloma that are proteasome inhibitor naive or have high-risk cytogenetics.
Read More
Developing Standard Operating Procedures for Using Bispecific Agents
November 23rd 2023During a Case-Based Roundtable event, Robert Mancini, PharmD, BCOP, FHOPA, discusses his experience setting up procedures for administering bispecific T-cell engagers for a large community oncology practice. This is the first of 2 articles based on this event.
Read More
Isatuximab Combo Provides Durable Option in High-Risk Multiple Myeloma
November 20th 2023In the first article of a 2-part series, Joshua Richter, MD, discussed how the triplet therapy of isatuximab, carfilzomib and dexamethasone, has impacted treatment considerations for patients with high-risk multiple myeloma.
Read More